Drug Trial Radar · NCT03323671
Preemptive Analgesia for Primary Dysmenorrhoea
Last checked: Nov 20, 2026Latest source record: Dec 19, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
84
Actual
Start
Aug 1, 2017
Primary completion
Dec 1, 2017
Study completion Dec 1, 2017
Sponsor
- Lead sponsor
- Hanan NabilAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 27, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Supportive care
- FDA-regulated drug
- No
- Who can join
- Female only, from 15 years, up to 25 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Preemptive analgesia before the release of pain mediators
Conditions
- Primary Dysmenorrhea
Interventions
preemptive mefenamic acidDrug
preemptive analgesia before menstrual pain
mefenamic acidDrug
mefenamic acid given only during menstruation
Primary outcomes
What the sponsor says the trial is designed to measure.
- change in the Degree of painTime frame: 4 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mansoura University
Al Mansurah, Egypt
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.